DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA361700
Title:
Antibody-IL2 Fusion Protein Delivery by Gene Transfer
Descriptive Note:
Annual rept. 1 Oct 97-30 Sep 98
Corporate Author:
WISCONSIN UNIV-MADISON
Report Date:
1998-10-01
Pagination or Media Count:
20.0
Abstract:
Our team has pursued preclinical and clinical investigations combining the administration of IL-2 with tumor reactive monoclonal antibodies. Preclinical models, developed by our collaborators R.Reisfeld and S.Gillies, have shown the antitumor efficacy of antibody-IL2 fusion proteins in murine models. The KS-IL2 fusion protein recognizes the KSA antigen expressed on a broad range of human carcinomas, including breast cancer and is effective at preventing outgrowth of the KSA positive, syngeneic CT26-KSA carcinoma cell line in mice. The experiments now underway in this research study are designed to help improve the future clinical efficacy of the KS-IL2 reagent by clarifying its actions, testing its efficacy in murine models simulating pitfalls with human immunotherapy, and translating these results to human application through in vitro studies.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE